Hansa Biopharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	178.61	171.32	134.09	154.53	33.88	6.1
Revenue Growth (YoY)	-5.69%	27.76%	-13.22%	356.12%	455.56%	81.27%
Cost of Revenue	72.39	83.55	63.14	38.48	15.43	1
Gross Profit	106.22	87.76	70.95	116.05	18.45	5.1
Selling, General & Admin	343.92	344.27	450.49	337.86	327.27	202.99
Research & Development	331.76	375.72	411.33	346.24	230.76	227.19
Other Operating Expenses	-0.53	-0.59	0.29	8.06	-	-
Operating Expenses	675.15	719.4	862.11	692.17	558.03	430.18
Operating Income	-568.93	-631.64	-791.16	-576.12	-539.58	-425.08
Interest Expense	-103.71	-134.08	-105.52	-43.67	-0.69	-0.26
Interest & Investment Income	149.78	20.83	28.06	8.83	0.07	0.39
Currency Exchange Gain (Loss)	-66.78	-71.98	37.81	5.95	-7.4	2.27
Other Non Operating Income (Expenses)	12.65	12.65	-	-4.97	-0.53	1.78
EBT Excluding Unusual Items	-576.99	-804.21	-830.81	-609.98	-548.13	-420.89
Pretax Income	-636.43	-804.21	-830.81	-609.98	-548.13	-420.89
Income Tax Expense	4.71	3.03	0.91	1.16	0.15	-0.04
Net Income	-641.14	-807.24	-831.72	-611.13	-548.28	-420.85
Net Income to Common	-641.14	-807.24	-831.72	-611.13	-548.28	-420.85
Shares Outstanding (Basic)	73	63	53	45	44	42
Shares Outstanding (Diluted)	73	63	53	45	44	42
Shares Change (YoY)	23.08%	19.59%	16.95%	1.01%	5.45%	5.39%
EPS (Basic)	-8.82	-12.85	-15.83	-13.60	-12.33	-9.98
EPS (Diluted)	-8.82	-12.85	-15.83	-13.60	-12.33	-9.98
Free Cash Flow	-501.05	-675	-755.94	-506.06	-483.57	-290.57
Free Cash Flow Per Share	-6.89	-10.74	-14.39	-11.27	-10.87	-6.89
Gross Margin	59.47%	51.23%	52.91%	75.10%	54.47%	83.65%
Operating Margin	-318.53%	-368.70%	-590.00%	-372.83%	-1592.71%	-6970.76%
Profit Margin	-358.96%	-471.20%	-620.25%	-395.49%	-1618.40%	-6901.49%
Free Cash Flow Margin	-280.52%	-394.01%	-563.74%	-327.50%	-1427.38%	-4764.97%
EBITDA	-566.58	-629.08	-788.33	-573.71	-538.06	-422.29
D&A For EBITDA	2.35	2.55	2.83	2.41	1.52	2.79
EBIT	-568.93	-631.64	-791.16	-576.12	-539.58	-425.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.